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TNF-stimulated gene-6 (TSG-6) is a multifunctional protein
secreted in response to pro-inflammatory stimuli by a wide
range of cells, including neutrophils, monocytes, and endothe-
lial cells. It has been shown to mediate anti-inflammatory and
protective effects when administered in disease models, in part,
by reducing neutrophil infiltration. HumanTSG-6 inhibits neu-
trophil migration by binding CXCL8 through its Link module
(Link_TSG6) and interferingwith the presentation ofCXCL8on
cell-surface glycosaminoglycans (GAGs), an interaction that is
vital for the functionofmany chemokines.TSG-6was also found
to interact with chemokines CXCL11 and CCL5, suggesting the
possibility that itmay function as a broad specificity chemokine-
binding protein, functionally similar to those encoded by
viruses. This studywas therefore undertaken to explore the abil-
ity of TSG-6 to regulate the function of other chemokines.
Herein, we demonstrate that Link_TSG6 binds chemokines
from both the CXC and CC families, including CXCL4,
CXCL12, CCL2, CCL5, CCL7, CCL19, CCL21, and CCL27. We
also show that the Link_TSG6-binding sites on chemokines
overlap with chemokine GAG-binding sites, and that the affini-
ties of Link_TSG6 for these chemokines (KD values 1–85 nM)
broadly correlate with chemokine-GAG affinities. Link_TSG6
also inhibits chemokine presentation on endothelial cells not
only through a direct interaction with chemokines but also by
binding and therefore masking the availability of GAGs. Along
with previouswork, these findings suggest that TSG-6 functions
as a pluripotent regulator of chemokines bymodulating chemo-
kine/GAG interactions, which may be a major mechanism by
which TSG-6 produces its anti-inflammatory effects in vivo.
TSG-6 (TNF-stimulated gene/protein 6) is an inflammation-
associated protein that has been shown to be up-regulated by
pro-inflammatory mediators such as IL-1, TNF, and LPS in a
broad range of cells and in the context of inflammatory diseases
(1–6). It is an35-kDa secreted protein composed of Link and
CUB_C domains with an additional short N-terminal sequence
(5, 7–10). Although initially found at high levels in the joints of
patients with rheumatoid and osteoarthritis, suggesting a pro-
inflammatory role (1), administration of TSG-6 was found to
inhibit damage in inflammatory models, including arthritis
(11–14) and transplant rejection (15), suggesting it possesses
anti-inflammatory properties. TSG-6 has also been identified
as a key mediator of anti-inflammatory effects of human mes-
enchymal stem cells inmodels ofmyocardial infarction (4), cor-
neal damage (16), peritonitis (17), traumatic brain injury (18),
acute lung injury (19), wound healing (20), and type 1 diabetes
(21). One mechanism underlying its protective effects is
thought to be its ability to inhibit the influx of neutrophils to
inflammatory sites and the concomitant neutrophil-induced
damage (4, 16, 18, 22, 23). To understand the basis for the pro-
tective effect of TSG-6, the Link module (Link_TSG6) was
expressed in isolation (24, 25) and shown to reproduce the
effects of the full-length protein in inhibiting neutrophil migra-
tion (26) and in binding to a number of ligands, including the
glycosaminoglycans (GAGs)4 heparin and heparan sulfate (HS)
(27, 28); moreover, Link_TSG6 inhibited rolling and transen-
dothelial migration of neutrophils as determined by intravital
microscopy (29). Link_TSG6 was also shown to interact with
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CXCL8 and to inhibit its presentation on and transport across
endothelial cells, as well as its ability to recruit neutrophils (30),
providing at least a partial explanation for the anti-inflamma-
tory effects of TSG-6.
CXCL8 is a member of the chemotactic cytokine (chemo-
kine) family of proteins, which are best known for their roles in
regulating cell migration. Theymediate cell recruitment by sig-
naling through chemokine receptors on leukocyte cell surfaces
(31–34). However, in addition to activating these G protein-
coupled signaling receptors on migrating cells, chemokines
interact with cell-surface GAGs (35–40). GAGs/proteoglycans
are found in the extracellular matrix (ECM) (41) and ubiqui-
tously on essentially all cell surfaces, including endothelial cells
where they comprise a key component of the glycocalyx (41–
44). The interaction of chemokines with GAGs enables their
cell surface localization and facilitates formation of chemotac-
tic gradients to guide leukocytes to sites of infection and inflam-
mation (40). Moreover, GAG binding has been shown to be
integral to the function of a number of chemokines, including
CXCL8 (38, 39), CXCL12 (37), CCL2 (35), CCL5 (35), CCL7
(36), and CCL21 (40).
Given the prior observation that TSG-6 inhibits binding of
CXCL8 to heparin and endothelial cell surfaces resulting in
down-regulation of CXCL8-mediated neutrophil migration
(30), we hypothesized that TSG-6might inhibit GAG-mediated
cell surface presentation of other chemokines that recruit dif-
ferent cell types (45). This hypothesis was motivated by the fact
that in addition to neutrophils, TSG-6 administration results in
reduced infiltration of other cell types during inflammation,
including monocytes (4), T cells, and dendritic cells (47).
In this study, we demonstrate the ability of Link_TSG6 to
interact with awide range of chemokines from theCC andCXC
subfamilies. Furthermore, we show that Link_TSG6 interacts
with the GAG-binding region of these chemokines and inhibits
their presentation on endothelial surfaces. These TSG-6/
chemokine interactions are of particular interest given the lack
of soluble chemokine-binding proteins identified in humans
and other vertebrates, despite many having been identified
in ticks, parasites, and viruses (48–50). Moreover, although
chemokines play an integral role in the regulation of inflamma-
tion, their pharmaceutical targeting has proved largely unsuc-
cessful, and such binding proteins could have therapeutic
potential (51, 52).
Experimental Procedures
Protein Production and Purification—WT Link_TSG6 and
the mutant Link_TSG6_T (K55A/K69A/K76A) (numbered as
in the pre-protein throughout (7)) were expressed in Esche-
richia coli and refolded/purified as described previously (24, 25,
27). Biotinylated andWTchemokinesCXCL4,CXCL12,CCL2,
CCL5, CCL7, CCL19, CCL21, and CCL27 and associated
mutants, where CCL21 CT relates to residues 1–79 as
described previously (53), were expressed and purified from
E. coli as described previously (54–56).
Surface Plasmon Resonance (SPR)—In all instances, a BIA-
core 3000 instrument (GE Healthcare) was used to generate
binding curves. Analyte was flowed over the chip surface in
running buffer (10 mM HEPES, 150 mM NaCl, 0.05% Tween 20
(v/v), pH 7.4) at varying concentrations for 5 min at 40 l/min;
subsequently, running buffer alone was flowed over the bound
ligand and a nonspecific control surface for 5 min at 40 l/min
to monitor the dissociation phase of the interaction. Curves
were then corrected with subtraction of nonspecific and buffer
alone signals and analyzedwith the BIAevaluation software (GE
Healthcare) using the 1:1 Langmuir interaction model. The
degree of fit to this model was assessed by using the 2 values,
where 210was accepted as a good fit. In the instances where
the 2 value was significantly higher than 10 and visual inspec-
tion of the data suggested poor fitting, alternative models were
used to fit the data (bivalent analyte or two-state reactionmod-
els); however, in no instances did these models improve the fit
to the raw data. Given the less than ideal fitting for some data-
sets involving chemokines with Link_TSG6, the calculated
affinities are considered “apparent affinities,” but they still
allow for relative ranking of the interactions. These difficul-
ties arise from the propensity of certain chemokines to oli-
gomerize, as described previously (57).
SPR Analysis of Chemokine Binding to Immobilized Link_
TSG6—The Link_TSG6 surface was generated on a C1 chip
(GE Healthcare) as described previously (30). Briefly, the sur-
face was activated with 100 l of a 1:1 mix of NHS (0.1 M)
and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.2 M)
before flowing over Link_TSG6 (20 g/ml) in immobilization
buffer (10 mM HEPES, pH 7.4) at 20 l/min until the desired
immobilization level was reached (800–1000 response units).
Remaining active sites on the chip surface were blocked with 1
M ethanolamine (120l). The surface was thenwashedwith 1 M
NaCl followed by regeneration buffer (50 mM NaOH). Results
from replicate chemokine injections before and after surface
regeneration and at various times throughout the use of a given
chip were used to monitor surface integrity; the data were
highly reproducible indicating that the Link_TSG6 surface was
unaffected by the regeneration treatment and remained stable
throughout the experiments. Interaction analysis was under-
taken as described above with a number of different chemo-
kines and associated mutants; any ligand remaining bound to
the Link_TSG6 surface was fully removed with regeneration
buffer (160 l) prior to the analysis of a different ligand.
SPR Analysis of Link_TSG6 Binding to Immobilized
Heparin—A heparin surface was generated on a C1 chip as
described previously (56). First, neutravidin was covalently
immobilized to the surface until saturation using the 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide/NHS chemistry de-
scribed above. The surface was then washed extensively to
remove non-covalently bound neutravidin before biotinylated
unfractionated porcine intestinal heparin (Calbiochem) (0.2
mg/ml in 100 mM sodium acetate, pH 5.5) was flowed over the
surface at 10l/min, until saturation was reached. SPR analysis
was carried out as described above to determine the affinity of
Link_TSG6 for immobilized heparin, using the same approach
described previously to analyze chemokine/heparin interac-
tions (56). Regeneration buffer was used following each cycle of
chemokine injection and interaction analysis to clean the chip
surface.
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Chemokine/Heparin Interactions in Solid Phase Binding
Assays—Solid phase binding assays were undertaken as de-
scribed previously (30). Briefly, CCL2, CCL7, CCL19, or
CXCL11 (250nM)was immobilized ontoNuncMaxiSorp plates
(ThermoScientific) in coating buffer (20 mM Na2CO3, pH 9.6)
for 16 h at room temperature. Wells were then rinsed using
assay buffer (10 mMNaOAc, 150 mMNaCl, 2% (v/v) Tween 20,
pH 6.0) and blocked with assay buffer containing 5% (w/v) BSA
at 37 °C for 90 min. Biotinylated heparin (made from 4th Inter-
national Standard (58)) was then added at increasing concen-
trations (0–100 ng/well), and for competition binding assays,
biotinylated heparin (25 ng/well) was added in combination
with a range of Link_TSG6_T concentrations (0–1000 nM) in
assay buffer at room temperature for 4 h. Plates were washed
with assay buffer, and the level of bound heparin was then
assessed by addition of ExtrAvidin-alkaline phosphatase
(1:10,000) (Sigma) and subsequent incubation with detection
reagent (SigmaFAST p-nitrophenyl phosphate solution (Sigma)).
After 5 min of development, absorbance levels (405 nm) were
taken and signal corrected against blank wells (no coated
chemokine); in cases where differential background of coated/
uncoated wells led to negative corrected values (i.e. at high
Link_TSG6_T concentrations), these were assigned a value of
0. Data were analyzed and fit to the non-linear regression one-
site bindingmodel (GraphPad PrismVersion 5.0) to provide an
estimate of the IC50 values.
Chemotaxis and Transendothelial Migration—Chemotaxis
experiments were undertaken using a 5-m pore Transwell
system (Corning Inc.) as described previously (56). Here,
CCL19 or CCL21 (50 nM) was pre-incubated alone or in com-
bination with different molar ratios of Link_TSG6 (1:2 or 1:1,
Link_TSG6:chemokine) for 30 min at 37 °C, 5% CO2 in 600 l
of Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS) in the bottom chamber of the
Transwell. L1.2 cells induced to express CCR7 or CCR5 (by
incubation with 5 mM sodium butyrate for 18 h), or Jurkat cells
expressing CXCR4, were resuspended in DMEM containing
10% FBS before addition to the top chamber of the Transwell
apparatus (100l of 2 106 cells/ml).Wells were incubated for
2 h at 37 °C, 5% CO2 before the suspended membranes were
removed, and the cells in the bottom chamber (migrated cells)
were counted using a Guava EasyCyte 8HT flow cytometer
(EMDMillipore). For transendothelial migration experiments,
EaHY926 human umbilical vein endothelial cells (100l of 1
106 cells/ml) were coated onto a suspended Transwell mem-
brane overnight in DMEM containing 10% FBS. The surface of
the endothelial cells was washed with 100 l of DMEM and
aspirated before the experiment was undertaken as described
above for chemotaxis experiments.
Endothelial/Collagen Chemokine Presentation Assay—These
assays were undertaken using a similar method to that
described previously (56). Specifically, a clear-bottomed black-
walled 96-well polystyrene plate (Corning Inc.) was coatedwith
200 l of 100 g/ml type I collagen (Purecol, Advanced Bio-
Matrix) for 1 h at 37 °C. EaHY926 human umbilical vein endo-
thelial cells were added to eachwell (200l of 0.1 106 cells/ml
(20,000 cells/well) in DMEM containing 10% FBS) and incu-
bated for 18 h (until confluent); this and all subsequent cellular
incubations were carried out in 5%CO2 at 37 °C. Non-adherent
cells were removed by washing with DMEM followed by two
washes with PBS supplemented with 1 mM CaCl2 and 0.5 mM
MgCl2 (cPBS). Alternatively, assays were undertaken on a col-
lagen-coated surface alone. Biotinylated chemokine (CXCL4,
CXCL12, and CCL21) or unlabeled chemokine (CCL2, CCL5,
and CCL7) was incubated alone or in combination with differ-
ent molar ratios of Link_TSG6 or heparin octasaccharide (dp8
(Neoparin); dp degree of polymerization) in cPBS for 30 min
at 37 °C before being added on top of the washed endothelial
monolayer and incubated for 1 h. Alternatively, Link_TSG6
(500 nM) was pre-incubated on top of the washed endothelial
cells for 30 min followed by three washes with cPBS and subse-
quent incubation of chemokine with endothelial cells for 1 h.
Chemokine/Link_TSG6 solutions were then aspirated and the
monolayers washed three times with cPBS for 2 min, before
fixation of cells with 150 l of ice-cold 4% (w/v) paraformalde-
hyde in PBS for 20 min at room temperature. These and subse-
quentwashes/incubationswere carried outwith gentle rocking.
The fixative agent was removed, and the endothelial cells were
washed (four incubations of 4 min) using PBS 0.05% Tween
20 before addition of 150 l of blocking solution (LI-COR Bio-
sciences) to each well and incubation for 90 min at room tem-
perature. The solution was aspirated, and in the case of bioti-
nylated chemokine, detection was undertaken with 100 l of
blocking solution containing streptavidin conjugated to IRDye
800CWbiotin detection reagent (LI-COR Biosciences; 1:1000),
which was added to eachwell and incubated for 90min at room
temperature. For non-labeled chemokine detection, 100 l of
blocking solution containing antibodies against CCL2, CCL5,
or CCL7 (R&D Systems, 1 g/ml) was added to each well and
incubated for 1 h at room temperature. Cells were then washed
four times (4min) with 100l of PBS 0.05%Tween 20, before
addition of anti-goat IgG 800CW conjugate (1:5000) (LI-COR
Biosciences) secondary antibody in blocking solution for 1 h at
room temperature. In all cases, the solution was aspirated from
the endothelial cells, which were then finally washed with 100
l of PBS  0.05% Tween 20 (four incubations of 4 min), fol-
lowed by bound chemokine detection using an Odyssey imag-
ing system (LI-COR Biosciences).
Cell Adhesion Assay—Murine bone marrow-derived den-
dritic cells (BMDCs) were cultured in DC media (RPMI 1640
medium, 10% FBS, 1% penicillin/streptomycin, 2 mM L-gluta-
mine, 10 mM HEPES, 1 mM non-essential amino acids, and 55
M -mercaptoethanol) in the presence of 20 ng/ml recombi-
nant murine GM-CSF (PeproTech) for 10 days. On day 9,
BMDCs were treated with 200 ng/ml lipopolysaccharide (LPS
055:B5 (Sigma)) for 24 h. One day prior to the assay, murine
lymphatic endothelial cells (SV-LECs, Alexander Laboratory,
LSU Cell Culture Repository, Louisiana State University) were
seeded onto a clear-bottomed, black-walled 96-well plate (Fal-
con) at 6.75 103 cells/well. Prior to use, BMDCs were stained
with calcein AM (eBioscience) for 1 h. Murine CCL21 (Bioleg-
end) alone or in the presence of a 1:1 molar eq of Link_TSG6
was diluted in serum-free DMEM, incubated at room temper-
ature for 30min, then added to the SV-LECs, and incubated for
an additional 30 min at 37 °C, 5% CO2. Following chemokine
incubation on the SV-LECs,mediumwas removed, and 1 104
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of calcein-labeled BMDCswere added to eachwell. After 5min,
cell fluorescence was measured on a plate reader (DTX880,
BeckmanCoulter) to determine themaximum fluorescence for
each well. Wells were then promptly washed two times with
PBS to remove unbound BMDCs and read again to determine
the extent of BMDC adhesion for each condition.
Results
TSG-6 Link Module Binds to Multiple Chemokines—Having
previously established that Link_TSG6 inhibits CXCL8-medi-
ated transendothelial migration of neutrophils via interactions
with CXCL8, we set out to investigate whether it also interacts
with other chemokines, explaining its ability to inhibit the
migration of diverse cell types (4, 47) and to produce anti-in-
flammatory effects (5, 8). For these experiments, we used SPR
with Link_TSG6 immobilized on an SPR chip and passed
chemokines over the surface at varying concentrations. The
rates of association (ka) and dissociation (kd) were determined
from the sensorgrams and used to calculate dissociation con-
stants (KD  kd/ka) with a 1:1 Langmuir interaction model.
Interestingly, the SPRdata revealed that Link_TSG6binds to 10
different chemokines (Table 1 and Fig. 1), including CXCL4,
CXCL11, CXCL12, CCL2, CCL7, CCL19, CCL21, and CCL27
(in addition to the known interactions with CXCL8 and CCL5
(30)) with KD values ranging from 1 to 85 nM. The chemokines
fall into three major groups where CXCL4 (3.9 nM), CXCL11
(5.2 nM), CCL5 (1.9 nM), and CCL21 (4.8 nM) comprise a high
affinity group (1–5 nM); CXCL8 (21 nM) (30), CXCL12 (15 nM),
CCL2 (29.4 nM), CCL7 (18.4 nM), and CCL19 (17.5 nM) have
slightly lower affinities (15–30 nM); and CCL27 showed the
weakest interaction (85.2 nM). A fourth category is also appar-
ent as Link_TSG6 has previously been shown to have little, if
any, affinity for CXCL1 or CCL3 (30).
GAG-binding Sites of All Chemokines Tested Are Important
for Interactions with TSG-6—Previous studies revealed that the
GAG-binding region of CXCL8 is involved in its interaction
with Link_TSG6 (30), leading us to hypothesize that GAG-
binding domains of the chemokines identified abovewill also be
important for Link_TSG6-chemokine complex formation. To
this end, we tested whether well characterized GAG-binding
deficient chemokine mutants, known to have significantly
impaired interactions with heparin or HS, also show a reduced
affinity for Link_TSG6. As demonstrated by the sensorgrams in
Fig. 2 and the calculated affinities in Table 1, this turned out to
be the case. Binding to Link_TSG6was effectively abolished for
the R18A/K19A mutant of CCL2 (59), the R44A/K45A/R47A
mutant of CCL5 (60), and a C-terminal deletion mutant of
CCL21 (53). Although interaction with Link_TSG6 could be
detected with the CCL7 mutant K18A/K19A/K22A (GAG-
binding null (56)), there was insufficient signal to calculate a
reliable dissociation constant, indicative of a weak interaction.
The CXCL12 GAG-binding deficient mutant K24S/H25S/
K27S (61) could still bind Link_TSG6 suggesting additional
epitopes contribute to the interaction; nevertheless, the affinity
was 55-fold lower than WT CXCL12. Similarly, the CCL27
K25A mutant displayed an 9-fold reduction in affinity for
Link_TSG6, and the retention of residual binding is unsurpris-
ing as a single point mutation would not be expected to com-
pletely eliminate GAG or protein binding. Finally, we could
detect only a weak interaction between Link_TSG6 and CCL3
(15mM (30)), similar to theweak-to-no interaction reported for
this chemokine with GAGs (57, 62). Recently, we published
apparent affinities determined by SPR for the interaction of HS
with CXCL4, CXCL8, CXCL11, CXCL12, CCL2, CCL5, CCL7
(56, 57), and CCL27. A plot of these apparent affinities against
Link_TSG6-chemokine affinities demonstrates that there is a
positive correlation (Fig. 3). Taken together, these data suggest
that the chemokine-binding sites for Link_TSG6 and GAGs
overlap, similar to the situation with CXCL8 (30).
TSG-6 Blocks Chemokine/GAG Interactions but Not Chemo-
kine/Receptor Interactions—The overlap between the Link_
TSG6- and GAG-binding sites on chemokines suggests that a
contributing mechanism by which TSG-6 exerts its anti-in-
flammatory function in vivo may be by blocking chemokine/
GAG interactions, which are known to be critical for chemo-
TABLE 1
Surface plasmon resonance analysis of chemokine andmutant affinities for a Link_TSG6-coated surface
Rates of association (ka) and rates of dissociation (kd) were used to calculate overall affinity (KD  kd/ka) values for chemokine binding to immobilized Link_TSG6. The
quality of the fit to a 1:1 Langmuir model is given by 2, and the Rmax (response units (RU)) values were calculated by application of this model, where 210 or 210%
of Rmax is indicative of a good fit. Data are representative of two independent experiments.
Chemokine ka kd KD 2 Rmax (RU)
M1 s1 s1 nM
CXCL4 3.6 105 1.4 103 3.9 52.9 270
CXCL8a 1.9 104 3.9 104 21 18.1 202
CXCL11 2.5 105 1.3 103 5.2 27.5 135
CXCL12 1.4 105 2.1 103 15 18.3 109
K24S/H25S/K27S 1.2 104 1.0 102 833.3 2.3 108
CCL2 5.1 104 1.5 103 29.4 5.5 80.3
R18A/K19A NOIb NOI NOI NOI NOI
CCL5a 5.7 104 1.1 104 1.9 7.3 265
R44A/K45A/R47A NPAc NPA NPA NPA NPA
CCL7 8.7 104 1.6 103 18.4 4.1 41.9
K18A/K19A/K22A NPA NPA NPA NPA NPA
CCL19 1.6 105 2.8 103 17.5 5.3 53.4
CCL21 7.1 105 3.4 103 4.8 18.7 99.5
CT NPA NPA NPA NPA NPA
CCL27 2.7 104 2.3 103 85.2 8.8 81.9
K25A 8.1 103 6.1 103 753.1 6.2 88.5
a Values for CXCL8 and CCL5 were previously reported in Ref. 30 and are shown here for comparison.
b NOI means no observable interaction.
c NPA means no possible analysis due to insufficient signal.
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kine function (35–40). To test this hypothesis, an ELISA-based
solid phase binding assay was devised. Specifically, CCL2 and
CXCL11 (representatives of CC and CXC chemokines, respec-
tively) were separately immobilized onto MaxiSorp plates and
incubated with increasing concentrations of heparin, resulting
in a saturating interaction between the chemokine and GAG
(Fig. 4A). These assays were then repeated with immobilized
chemokine (CXCL11, CCL2, CCL7, or CCL19) in the presence
of a fixed, saturating concentration of heparin in combination
with increasing concentrations of the Link_TSG6_T (K55A/
K69A/K76A) mutant (Fig. 4, B and C); this mutant was chosen
because it has greatly reduced ability to bind heparin (27) and
thereby simplifies the interpretation of the resulting data. In
line with the above hypothesis, the Link_TSG6mutant resulted
in a dose-dependent inhibition of the binding of all the chemo-
kines tested to heparin with IC50 values estimated to be 168 nM
(CXCL11), 84 nM (CCL2), 159 nM (CCL7), and 55 nM (CCL19).
To investigate whether Link_TSG6 inhibits the interaction
of chemokines with receptor in addition to interactions with
GAGs, we conducted bare filter chemotaxis assays in which
chemokine was placed in the bottom well of a Transwell appa-
ratus, and L1.2 cells, transfected with appropriate receptor,
were placed in the top well. Similar to a previous study where
Link_TSG6 had no effect on the migration of CXCR1-express-
ing cells (30), Link_TSG6 did not affect themigration of CCR5-
or CCR7-bearing L1.2 cells toward CCL5, CCL19, or CCL21 or
of Jurkat cells that endogenously express CXCR4 toward
CXCL12 in the bare filter assay (Fig. 5). These data suggest that
although Link_TSG6 directly binds these chemokines, it does
not block their interaction with their respective receptors.
Link_TSG6 Inhibits Chemokine Presentation on Endothelial
Cells and Collagen and Subsequent Chemokine-mediated Cell
Adhesion—The finding that Link_TSG6 interacts with the
GAG-binding region of chemokines led us to test whether
Link_TSG6 could affect chemokine binding and presentation
on endothelial cells, a process known to be mediated by cell-
surface GAGs (63, 64). Pre-incubation of Link_TSG6 with six
different chemokines resulted in reduced chemokine accumu-
lation on endothelial cells in all cases except CCL5 (Fig. 6). The
potency of its inhibitory trend was chemokine-specific as a 1:1
Link_TSG6/chemokine molar ratio was sufficient to signifi-
cantly reduce the endothelial cell accumulation of CCL7 (down
to 50% of the level of chemokine alone), CCL21 (50% of chemo-
kine alone), and CCL2 (75 and55% of chemokine alone at a
1:1 and 5:1 ratio, respectively, Fig. 6, A–C). However, CXCL12
and CXCL4 required a 5-fold molar excess of Link_TSG6 to
reduce accumulation to 68 and 51%of chemokine alone, respec-
tively (Fig. 6, D and E, respectively); lower ratios of Link_
TSG6/CXCL4 had no effect on endothelial binding of the
chemokine (data not shown). No inhibition of CCL5 was
observed at a 5:1 ratio of Link_TSG6 to chemokine (Fig. 6F).
Importantly, when the experiment was performed using hepa-
rin dp8 instead of Link_TSG6 in the same molar excess that
caused reduced chemokine binding with Link_TSG6, a similar
inhibition of chemokine accumulation on the endothelial cells
was observed forCCL7, CCL21, CCL2, andCXCL4 (Fig. 6,A–C
and E, respectively). In the case of CXCL12, pre-incubation
with either heparin dp8 or Link_TSG6 had similar inhibitory
effects on chemokine accumulation, although in contrast to
Link_TSG6, the effect of heparin did not reach significance
(Fig. 6D).
FIGURE 1. Multiple chemokines bind to immobilized Link_TSG6. Link_
TSG6 was immobilized onto a BIAcore C1 chip, and different chemokines
were passed over in running buffer at various concentrations to generate
affinity estimates. Experimental curves are plotted (black lines) with fits (red
lines) generated from a 1:1 Langmuir interaction model using analytes at a
range of concentrations to generate “on” (ka) and “off” (kd) rates for the inter-
action and overall affinity (KD kd/ka). A, CXCL4 (400, 200, 100, 50, 40, and 40
nM). B, CXCL11 (200, 150, 100, 75, and 50). C, CXCL12 (400, 200, 100, 50, 40, 40,
25, 12.5, and 6.25 nM).D, CXCL12 K24S/H25S/K27S (200, 150, 100, 75, 50, 37.5,
37.5, 25, and 12.5 nM). E, CCL2 (1000, 750, 500, 400, 250, 250, 200, 100, and 50
nM). F, CCL7 (1000, 750, 500, 400, 250, 250, 200, 100, 50, and 25 nM). G, CCL19
(200,150, 100, 75, 50, 37.5, and 25 nM). H, CCL21 (200, 150, 100, 75, 50, 37.5,
37.5, 25, and 12.5 nM). I, CCL27 (1000, 500, 400, 250, 250, 200, 100, and 50 nM).
J, CCL27 K25A (1000, 750, 500, 400, 250, 250, 200, 100, and 50 nM). RU,
response units.
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Link_TSG6was previously demonstrated to have amoderate
affinity (3 M) interaction with dp8 heparin by isothermal
titration calorimetry (27). By comparison and as shown by the
SPR data in Fig. 7, Link_TSG6 binds unfractionated heparin
(average molecular mass  15 kDa, dp 10–80) with higher
affinity (22 nM); this is not surprising because larger GAGs
have been observed to have higher affinity for chemokines (62).
This affinity is in the range of chemokine/heparin interactions
(57), which prompted us to investigate whether Link_TSG6
could also affect chemokine/endothelial cell surface binding
when incubated with the cells prior to introduction of chemo-
kine. This experimental design specifically addresses an alter-
nativemechanism of inhibition, where Link_TSG6 binds endo-
thelial GAGs, and thereby affects subsequent chemokine/GAG
interactions. In this experiment, Link_TSG6 inhibited the
accumulation of CXCL4 (33% inhibition), CXCL12 (36% inhi-
bition), CCL2 (42% inhibition), CCL7 (32% inhibition), CCL21
(17% inhibition), and CCL5 (45% inhibition) on endothelial cell
surfaces (Fig. 8). These data suggest that Link_TSG6 can pre-
vent endothelial presentation via a direct interaction with
chemokines and also by masking or limiting available cell-sur-
face GAGs.
Chemokines are found abundantly in the ECM (31), and
TSG-6 is known to function in the ECM (5, 9, 10). Thus, follow-
ing our observations that Link_TSG6 can inhibit chemokine
presentation on endothelial cells, we investigated whether it
inhibits chemokine binding to collagen, an important compo-
nent of the ECM. In agreementwith previous studies describing
chemokine/collagen interactions (65, 66), we observed that
CCL21, CXCL12, and CXCL4 bind to collagen-coated surfaces
(Fig. 9A). Notably, pre-incubation of these chemokines with
Link_TSG6 resulted in dose-dependent inhibition of their
binding to collagen (Fig. 9,B–D). These findings suggest TSG-6
may function as a general modulator of chemokine presenta-
tion on endothelial cell HS and extracellular matrix compo-
nents, including GAGs and collagen.
Link_TSG6 did not inhibit the interaction of chemokines
studied herein with their receptors as shown by its inability to
affect cell migration in an in vitro bare filter chemotaxis assay.
However, because Link_TSG6 inhibits presentation on endo-
thelial GAGs, we questioned whether it would inhibit transen-
dothelial cell migration, a process that requires transport of
chemokine across the endothelial layer and can involve GAG-
dependent transcytosis (30, 64, 67). Moreover, in a previous
study, Link_TSG6 significantly inhibited transendothelial
migration of cells toward CXCL8, which correlated with
impaired CXCL8 transcytosis and impaired presentation of the
chemokine on the apical surface (30). In this study, it inhibited
CCL19- and CCL21-mediated transmigration of L1.2/CCR7
cells, albeit modestly, at both 1:2 (22 and 19% inhibition,
respectively) and 1:1 (26 and 18% inhibition, respectively)
Link_TSG6/chemokine ratios (Fig. 10). As transcytosis has
been suggested to account for only 10% of chemokine trans-
port, with pericellular transport by diffusion of chemokine
FIGURE 2. Chemokines bind Link_TSG6 through their GAG-binding epitopes. Link_TSG6 was immobilized onto a C1 chip. Chemokines and their corre-
sponding GAG-binding mutants were then passed over the immobilized Link_TSG6 at 40 l/min, and the resulting interaction was monitored. The response
units (RU) on the y axis reflect the amount of chemokine bound as follows. A, CCL2 and R18A/K19A (1000 nM). B, CCL5 and R44A/K45A/R47A (200 nM). C, CCL21
and C-terminal truncated mutant (200 nM). D, CCL7 and K18A/K19A/K22A (1000 nM). E, CXCL12 and K24S/H25S/K27S (200 nM). F, CCL27 and K25A (1000 nM).
FIGURE 3.Correlationbetween chemokine affinity for Link_TSG6andHS.
Kinetic affinity estimates for each chemokine binding to immobilized HS (56,
57) or Link_TSG6 are plotted, as calculated using SPR. Data shown are from
individual measurements representative of two independent experiments.
CXCL8 is excluded from this figure as previous studies did not enable evalu-
ation of a robust affinity estimate for the CXCL8/HS interaction (57).
TSG-6 Inhibits Chemokine/Glycosaminoglycan Interactions
12632 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 24•JUNE 10, 2016
through gaps between endothelial cells accounting for90% (64),
it isnot surprising thatonlymodest inhibitionwasobserved.Addi-
tionally, we did not observe any inhibitory effects on CXCL12- or
CCL5-mediated transmigrationof receptor-bearing Jurkat orL1.2
cells, respectively (Fig. 10, C and D), which suggests that these
chemokinesare transportedpredominantlybyapericellular route.
Although only modest inhibition of CCL21-mediated transendo-
thelial cell migration was observed, we sought to determine
whetherLink_TSG6coulddisrupt other steps in this process. Spe-
cifically, inhibition of dendritic cell adhesion to the endothelium
was tested, given the established reduction in CCL21 accumula-
tion on the apical surface of endothelial cells in the presence of
Link_TSG6(Fig.6B).Pre-incubationofCCL21withLink_TSG6at
a 1:1 molar ratio significantly reduced CCL21-mediated BMDC
adhesion to close to control levels (with amean value of 40% inhi-
bition and a range of 23–71% inhibition across replicate experi-
ments) (Fig. 10E). This finding provides additional evidence for a
biologically relevant consequence of TSG-6-mediated regulation
of chemokine function.
Discussion
TSG-6 Link Module Mediates Binding to Multiple Chemo-
kines—Given that Link_TSG6 inhibits neutrophil recruitment
and associated inflammation by blocking the function of
CXCL8, we set out to test whether it inhibits the function of
other chemokines. These studies were also motivated by its
broad anti-inflammatory effects in several disease models
where a wide range of other chemokines and cell types play a
role (4, 11–19, 22, 23). Indeed, we demonstrated that Link_
TSG6 binds to multiple chemokines from both the CC and
CXC families, including CXCL4, CXCL11, CXCL12, CCL2,
CCL5, CCL7, CCL19, CCL21, and CCL27. This group not only
includes chemokines from two of the four chemokine subfam-
ilies but also those classified as inflammatory (CXCL4, CXCL-
11, CXCL12, CCL2, CCL5, and CCL7) versus homeostatic
(CCL19 and CCL21) (68, 69).
The fact that TSG-6 binds to most chemokines tested raises
the question as to the likelihood that it would be present in the
same location as these chemokines in vivo. TSG-6 expression
during inflammation is well established (5, 8), and it is known to
be secreted by inflammatory cells such as peripheral blood
mononuclear cells (1, 7, 70), neutrophils (71), mast cells (72),
and macrophages (71, 73) in response to signals, including LPS
and TNF (1, 7, 70, 71). TSG-6 is also produced by stromal cells
such as fibroblasts (7, 74) and human umbilical vein endothelial
FIGURE 5. Pre-incubation with Link_TSG6 has no effect upon CCL5-,
CCL19-, CCL21-, or CXCL12-mediated chemotaxis of CCR7-, CCR5-, or
CXCR4-expressing cells. A–D, CCL5 (1 nM), CCL19 (50 nM), CCL21 (50 nM), or
CXCL12 (1 nM) was added to the bottom chamber of a Transwell systemwith
or without pre-incubation with the indicated molar ratio of Link_TSG6 (Link_
TSG6/chemokine). CCR5-expressing (A), CCR7-expressing (B and C), and
CXCR4-expressing (D) cells were added to the top well of the suspended
membrane; following incubation (2 h, 37 °C), the numbers of migrated cells
were counted. Data are normalized to the level of migration mediated by
chemokine alone and plotted as mean values (	S.E.) from two independent
experiments, each undertaken in duplicate (n 2).
FIGURE4.Link_TSG6 inhibits the interactionof chemokineswithheparin.
Chemokine (250 nM) was immobilized onto MaxiSorp plates and incubated
with increasing amounts of biotinylatedheparin (0–100ng/well), plateswere
then washed, and bound heparin was detected (A). CXCL11 or CCL2 (250 nM)
(B) and CCL7 or CCL19 (250 nM) (C) were immobilized onto MaxiSorp plates
and then incubated with a constant amount of biotinylated heparin (25
ng/well) in combination with increasing concentrations of the Link_TSG6_T
mutant (K55A/K69A/K76A) (0–1000 nM), which has reduced heparin binding
activity. The amount of bound biotinylated heparin was then detected and
plotted as a percentage of themaximumbinding observed in the absence of
competitor. Data are plotted as themean of three independent experiments
(	S.E.), each undertaken in quadruplicate (n  3) with background signal
subtracted.
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cells (71). Likewise, many chemokines are associated with
inflammation (32, 34) and are expressed by a similar range
of inflammatory (45, 76–78) and endothelial (79, 80) cells.
Unlike inflammatory chemokines, CCL19 and CCL21 are asso-
ciated with lymphatic trafficking of dendritic cells via CCR7
(81); thus, their expression is more limited to cells in lymphatic
vessels. Nevertheless, the fact that monocyte-derived dendritic
cells produce TSG-6 in response to LPS (71) suggests that lym-
phatic dendritic cells could also produce TSG-6. Similarly,
human umbilical vein and microvascular endothelial cells have
been shown to produce TSG-6 (71, 82), and TSG-6 has been
implicated in the function of HA binding to the LYVE-1 recep-
tor on lymph vessel endothelial cells (83). Overall, it seems
likely that TSG-6 and chemokines would be co-expressed in
vivo at sites of inflammation and in the lymphatic system.
TSG-6 Interacts with Chemokines through Their GAG-bind-
ing Sites and Inhibits Their Binding to GAGs and Endothelial
Cell Surfaces—In previous studies of CXCL8 (30), it was shown
that Link_TSG6 does not exert its inhibitory effects by disrupt-
ing chemokine/receptor interactions (except at high micromo-
lar concentrations in the case of CXCR2). Instead, it primarily
blocks the interaction of CXCL8 with GAGs (27), which indi-
rectly affects cellmigration (35–40). Chemokine/GAG interac-
tions are thought to be required for the formation of chemokine
gradients on cell surfaces and in the ECM, as demonstrated for
CCL21 in the context of dendritic cell recruitment (40). More-
over, GAG-binding deficient mutants of CXCL8, CXCL12,
CCL2, CCL5, andCCL7 all show a significantly impaired ability
to recruit cells in vivo, despite their capacity to promote cell
migration in bare filter chemotaxis assays where GAG binding
is not required (35–37, 39). Given the prior data on CXCL8, we
hypothesized that TSG-6 would also target the GAG-binding
sites of the chemokines identified as ligands in this study.
Indeed, we showed that mutation of GAG-binding residues in
chemokines greatly reduced the affinity of Link_TSG6. Thus, it
was not surprising to find that incubation of Link_TSG6 with
most of the testedWT chemokines inhibited their presentation
on endothelial cell surfaces (Fig. 11, A and C). Furthermore,
Link_TSG6 was as effective as heparin at inhibiting endothelial
presentation (when used at an equivalent molar ratio), and it
also blocked binding of chemokines to collagen, an important
component of the ECM.
FIGURE 6. Pre-incubation of chemokine with Link_TSG6 inhibits subsequent presentation on the endothelial cell surface. CCL7 (50 nM) (A), CCL21 (50
nM) (B), CCL2 (50 nM) (C), CXCL12 (50 nM) (D), CXCL4 (10 nM) (E), and CCL5 (10 nM) (F) were incubated either alone or in combination with different molar ratios
of Link_TSG6or heparin dp8 (ratios given as Link_TSG6/chemokineor dp8/chemokine) prior to incubationon the endothelial cell surface, followedbywashing
anddetection of bound chemokine. Data are expressed as a percentageofmaximal bindingof chemokine alone andplotted asmean values (	S.E.) from three
independent experiments, each undertaken in duplicate (n 3). *, p 0.05; **, p 0.01; ***, p 0.001 (comparedwith chemokine-only controls), and ns no
significant difference (p
 0.05) between samples treatedwith equivalentmolar ratios of Link_TSG6 and dp8, as determined using repeatedmeasures ANOVA
analysis with a Bonferroni post hoc test.
FIGURE 7. Link_TSG6 binds immobilized heparin. Heparin was immobi-
lized onto a C1 BIAcore chip before Link_TSG6 was passed over in running
buffer at a range of concentrations (750, 500, 400, 250, 200, 100, and 50 nM).
Rates of association (ka) and rates of dissociation (kd) were used to calculate
overall affinity (KD  kd/ka). The quality of the fit to a 1:1 Langmuir model is
given by 2 values calculated by application of this model, where 2 10 is
indicative of a good fit.
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FIGURE 8. Pre-incubation of Link_TSG6 on the endothelial cell surface inhibits subsequent chemokine presentation. Endothelial monolayers were
incubatedwith/without Link_TSG6 (500nM) followedbywashingandadditionofCCL7 (50nM) (A), CCL21 (50nM) (B), CCL2 (50nM) (C), CXCL12 (50nM) (D), CXCL4
(10nM) (E), andCCL5 (10nM) (F) to theendothelial cell surface; afterwashing, the level ofboundchemokinewasdetermined.Data areexpressedas apercentage
ofmaximal bindingof chemokine alone, plotted asmean values (	S.E.) from three independent experiments, eachundertaken in duplicate (n 3). *,p 0.05;
**, p 0.01 (compared with chemokine-only controls), as determined using Student’s t test.
FIGURE 9. Pre-incubation of chemokine with Link_TSG6 inhibits subsequent presentation on collagen. Biotinylated CCL21, CXCL12, or CXCL4 were
incubated at different concentrations (10, 50, or 200 nM) on wells pre-coated with collagen, and the amounts bound following washing were detected using
labeled streptavidin (A). Thebiotinylated chemokines CCL21 (50nM) (B), CXCL12 (50nM) (C), or CXCL4 (10nM) (D) were incubated either aloneor in combination
with different molar ratios of Link_TSG6 (ratios given as Link_TSG6/chemokine) prior to incubation on the collagen-coated surfaces, followed by detection as
before. Data are expressed as total binding (relative fluorescence intensity) (A) or as a percentage of maximal binding of chemokine alone (B–D), plotted as
mean values (	S.E.) from two independent experiments, each undertaken in duplicate (n  2). *, p  0.05; **, p  0.01 (compared with chemokine-only
controls), as determined using repeated measures ANOVA analysis with a Bonferroni post hoc test.
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The exception to these findings was the lack of inhibition of
CCL5 binding to endothelial cells following pre-incubation
with Link_TSG6, despite the high affinity interaction between
the two. Themechanistic reason for the anomalous behavior of
CCL5 is unknown; however, CCL5 is unique in forming large
stable polymers in solution, and it has a very high affinity for
cell-surface GAGs because of avidity effects from multiple
GAG-binding sites on its surface (57). Although speculative, it
may be that upon pre-incubation with CCL5, TSG-6 is unable
to mask all GAG-binding sites on the CCL5 polymer and that
the remaining GAG sites are still permissive to its interaction
with cell-surface GAGs. However, when TSG-6 is pre-incu-
bated with the endothelial surface, it may be a more effective
mechanism for blocking the subsequent binding of CCL5 by
sterically preventing the formation of high affinity GAG-CCL5
polymer complexes that would normally occur. Further studies
will be required to test this possibility.
In addition to inhibiting the binding of chemokines to endo-
thelial cells by interacting with the GAG-binding epitopes on
chemokines, we showed that TSG-6 can directly interact with
and thereby mask cell-surface GAGs (Fig. 11, A and B). In sup-
port of these findings, it is well established that the Link_TSG6
interacts with a wide variety of GAGs, including chondroitin
sulfate (CS), dermatan sulfate, heparin/HS, and HA (27, 28).
Furthermore, in this study we demonstrate that Link_TSG6
binds to heparin with an affinity (20 nM) that is similar to its
affinity for several chemokines (56, 57). We also showed that
the affinities of chemokines for Link_TSG6 strongly correlate
with their affinities for HS. This “matching” of binding
strengths would be expected to allow TSG-6 to modulate
chemokine binding to GAGs in a highly concentration-depen-
dent manner.
The ability of the TSG-6 Link module to dimerize when
bound to heparin and CS (27, 84) may contribute to its potency
in sequestering chemokine-binding sites on GAGs through an
avidity effect. Cross-linking of GAGs by TSG-6 may also affect
the accessibility or conformation of chemokine-binding sites
on GAGs. Finally, binding of the CUB_C domain to fibronectin
in the context of full-length TSG-6 (85) may provide additional
tethers that further strengthen its interactions with GAGs, col-
lagen, and/or other ECM substrates. Collectively, these mech-
anisms for sequestering chemokine-binding sites on endothe-
lial and ECM GAGs may contribute to the broad spectrum
activities of TSG-6, enabling it to affect not only the chemo-
kines investigated here but any chemokine whose function is
dependent on GAG binding.
By inhibiting the presentation of chemokines on cell-surface
GAGs and collagen, Link_TSG6 is predicted to cause the dis-
ruption of chemokine gradients, resulting in impaired cell
migration (40). However, the in vitro migration assays used in
this study are inadequate for testing this hypothesis because,
apart from a potentially small contribution of GAG-mediated
transcytosis on cell migration, there is little or no dependence
of transendothelial migration on GAG interactions. This is due
to the fact that Transwell migration assays automatically estab-
lish a chemokine gradient by the separation of chemokine and
cells between the two chambers, eliminating the need for
GAGs. Furthermore, sample confinement in the wells and lack
of shear forces/flow prevent rapid dissipation of chemokines
that might otherwise happen in vivo in the absence of GAG
interactions (35). More complex in vitro (under flow) or in vivo
assays will be required to further probe the mechanistic basis
for the anti-inflammatory properties of TSG-6 with respect to
how it affects gradient formation of chemokines and subse-
quently cell migration, similar to previous studies with GAG
binding-deficient chemokines (35–37, 39).
Insights into the Recognition between Chemokines and
TSG-6—In this study, we showed that TSG-6 binds to all
chemokines tested through their GAG-binding sites. The high
FIGURE 10. Pre-incubation with Link_TSG6 inhibits CCL19- and CCL21-
mediated but not CXCL12- or CCL5-mediated transendothelial migra-
tion of CCR7-, CXCR4-, or CCR5-expressing cells, and CCL21-mediated
adhesion of BMDCs.CCL19 (50 nM), CCL21 (50 nM), CXCL12 (1 nM), or CCL5 (1
nM) was added to the bottom chamber of a Transwell with or without pre-
incubation with the indicated molar ratios of Link_TSG6 (Link_TSG6/chemo-
kine) andCCR7- (AandB), CXCR4- (C), orCCR5 (D)-expressingcellswereadded
to the topwell in thepresenceof anendothelialmonolayer on the suspended
membrane; following incubation (2 h, 37 °C), the numbers of migrated cells
were counted. Data were normalized to the level of migration mediated by
chemokine alone, plotted as mean values (	S.E.) from three independent
experiments, each undertaken in duplicate (n  3). *, p  0.05; **, p  0.01
(comparedwithchemokine-onlycontrols),asdeterminedusingrepeatedmea-
sures ANOVA analysis with a Bonferroni post hoc test. CCL21 (10 nM), pre-
incubated at a 1:1 molar ratio with Link_TSG6, was incubated with
SV-LECs (30min, 37 °C) followed by addition of BMDCs. BMDC adhesion (per-
centage of total maximal signal) is plotted as mean values for triplicate wells
(	S.D.) froma representativedata setof six independentexperiments (E). ***,
p 0.001 for CCL21 alone compared with vehicle control or for Link_TSG6/
chemokine compared with CCL21 alone, as determined using a one-way
ANOVA analysis with a Bonferroni post hoc test.
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resolution molecular details of how it does so remains an
important question because chemokines are overall basic pro-
teins, but TSG-6 is basic as well (pI 9.48 (84)). Previously, it
was shown that a mutant of Link_TSG6 (Link_TSG6_T), with
reduced capacity to bind heparin (27), was still capable of bind-
ing to CXCL8 and inhibiting both its interaction with GAGs
and transendothelial cell migration toward CXCL8 (30). Simi-
larly, in this study, we showed that this Link_TSG6 mutant
could inhibit CXCL11, CCL2, CCL7, and CCL19 interactions
with heparin. These findings suggest that the heparin-binding
site on Link_TSG6 (Fig. 12) does not overlap with its binding
site for CXCL8 and the above chemokines, whichmay very well
be the case for other chemokines. This would not be surprising
because the heparin-binding surface of Link_TSG6 is com-
posed of basic residues, making it incompatible with chemo-
kine GAG-binding sites, which are also defined by clusters of
Arg, Lys, and His (86, 87). Instead, the interaction with the
GAG-binding domains of chemokinesmay bemediated by neg-
atively charged amino acids in Link_TSG6 (Fig. 12). Alterna-
tively, as the binding site on Link_TSG6 for HA/CS is non-
overlapping with heparin and enriched with aromatic residues,
it is possible that it could provide a binding site for chemokines
(Fig. 12). In this case, favorable cation/ interactions (88, 89)
between the Link_TSG6 aromatic residues and Lys/Arg resi-
dues in the chemokineGAG-binding epitopes could contribute
to complex formation. Identification of the chemokine-binding
sites on TSG-6 will be the subject of future studies.
The present data also suggest that, although the binding sites
for chemokines and heparin on Link_TSG6 do not overlap, it is
probable that chemokine and heparin (and likely HS) do not
simultaneously bind the Link module (Fig. 11). This is because
Link_TSG6 blocks cell surface presentation of chemokines, and
if GAG and chemokine could both bind to the Link module,
then the opposite effect might be expected. This suggests that
an allosteric mechanism may prevent simultaneous binding of
GAG and chemokine, as has been suggested for the competing
interactions of HA and heparin for their distinct binding sites
on Link_TSG6 (27, 84). Alternatively, if chemokines bind to the
HA/CS-binding site of TSG-6 (27, 84), then binding of chemo-
kine and these GAGs to TSG-6 would simply be competitive
and mutually exclusive.
In addition to basic epitopes defining the GAG-binding sites
of chemokines, many chemokines oligomerize by themselves,
and the oligomers are stabilized by GAGs (56, 90–93). Further-
more, oligomerization plays a critical role in the affinity of
chemokines for heparin,HS, andCS (39, 56, 57, 94).Whether or
not chemokine oligomerization affects binding to Link_TSG6
is not yet clear and will also be the subject of future studies.
TSG-6 Is a Broad SpectrumChemokine-binding Protein—We
previously identified TSG-6 as the first knownmammalian sol-
uble chemokine-binding protein (30) and can now further
define it as a broad spectrum chemokine-binding protein that
interacts with multiple chemokines via their GAG-binding
domains. Thus, the cumulative abilities of TSG-6 to inhibit
chemokine interactions with GAGs as well as collagen, to exert
inhibitory effects in the ECM and on cell surfaces, and to
directly bind chemokines and GAGs together create a robust
mechanism by which TSG-6 is able tomodulate the function of
many chemokines with potentially significant anti-inflamma-
tory consequences (11–14, 16–19, 23). In fact, TSG-6may rep-
resent a general regulator of heparin/HS-binding proteins; in
addition to 10 chemokines, TSG-6 interacts with seven hepa-
rin/HS-binding bone morphogenetic proteins (95), at least in
part, via its Linkmodule.How a single protein can bind somany
FIGURE11.ModelofTSG-6 inhibitionof chemokine/GAG interactions.A, chemokines (green) bind toGAGs (branched structures) presentonendothelial cells
(shown) and within the ECM (not shown) via GAG-binding sites on the chemokine (depicted as dark line). Integral to their function, chemokine/GAG interac-
tions enable the retention and accumulation of chemokines on cell surfaces, which leads to the formation of chemokine gradients involved in directing cell
migration. In inflammatory settings, TSG-6 (purple) is up-regulated and inhibits chemokine function by blocking the cell surface presentation of chemokines (B
and C). One mechanism for how TSG-6 can exert its inhibitory effects is by directly binding to GAGs on the cell surface, thus limiting available GAG for
chemokine interactions (B). Additionally, TSG-6 binds chemokines directly through their GAG-bindingdomains, therebyblocking chemokine interactionswith
GAG by competing for a common binding surface (C).
FIGURE 12. Interaction sites for CS/HA, heparin, and potential binding
sites for chemokines on Link_TSG6. Structure of a Link_TSG6 complexwith
CS (Protein Data Bank code 2N40) is shown, where Link_TSG6 is represented
as a surfacemesh, and CS is shown as a space-fillingmodel. The green surface
of Link_TSG6 highlights the aromatics that define the CS/HA-binding site (9,
84) and could provide a binding site for chemokines through their GAG-bind-
ing epitopes. The blue surface highlights the basic residues that define the
heparin-binding site as determined previously (75), which is not compatible
with chemokine binding. The red surface highlights Glu residues that could
provide a binding site for chemokines through their GAG-binding epitopes.
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other proteins is reminiscent of viral chemokine-binding pro-
teins that promote virulence by sequestering chemokines and
suppressing the immune response (96). For example, the
chemokine-binding proteinM3, produced by -herpesvirus 68,
can bind to both receptor- and GAG-binding domains of
chemokines (97), thereby inhibiting chemokine function by
two separate mechanisms. E163 from poxvirus is similar to
TSG-6 in that it interacts with chemokines through their GAG-
binding epitopes and also binds directly to GAGs, but it does
not inhibit interactions of chemokineswith their receptors (46).
The similarity of TSG-6 with these various chemokine-binding
proteins underscores its role as a pluripotent anti-inflamma-
torymediator of chemokine function. Its ability to interact with
so many chemokines may add to its known functions in the
ECM and explain some of its protective effects in models of
inflammatory disease (11–14) and its more recently described
role in protection against inflammatory damage mediated by
humanmesenchymal stemcells (4, 16–18, 23). Inhibition of the
presentation of chemokines on cell surface and ECM GAGs
would be expected to impair leukocyte migration in vivo due to
the lack of an immobilized chemokine gradient for the cells to
follow (40). Thus, TSG-6 expressionmay provide a novelmech-
anismwhereby cellular presentation of chemokines can be reg-
ulated and finely tuned.
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